Temferon™: Overview

Genenta Science, has developed a proprietary hematopoietic stem cell-based platform for the targeted delivery of therapeutic payloads in oncology. The company's research activities span preclinical development, clinical investigation, and collaborations with leading international research institutions.

Scientific Rationale and Technology Platform

Solid tumors are highly complex biological systems composed not only of malignant cells but also of diverse resident and recruited host cell types, soluble factors, and extracellular matrix components. The tumor microenvironment (TME) is a dynamic network in which the interplay of cellular and molecular elements actively suppresses anti-tumor immune responses, enabling cancer cells to evade natural immune defenses.

Prominent among the immunosuppressive elements within the TME are Tie2-Expressing Monocytes (TEMs), a subset of tumor-associated myeloid cells first characterized in 2005 by Luigi Naldini and colleagues at the San Raffaele Scientific Institute. When recruited to tumors from peripheral blood — where they are continuously replenished from bone marrow-resident hematopoietic stem cells — TEMs promote tumor vascularization (angiogenesis) and suppress local immune activity, thereby facilitating tumor progression.

The platform exploits TEMs as precision delivery vehicles. By genetically engineering a patient's own HSPCs to express immunotherapeutic payloads specifically upon differentiation into TEMs within the TME, the platform enables localized and sustained therapeutic activity while minimizing systemic toxicity — one of the principal limitations of conventional immunotherapy approaches.

The proprietary transgene expression control system operates through dual regulation at the transcriptional and post-transcriptional levels. A Tie2 promoter restricts transgene transcription to TEMs within the TME, while miRNA-126 target sequences suppress expression in undifferentiated hematopoietic stem and progenitor cells, ensuring a highly controlled therapeutic window.

Temferon™: Product Description

Temferon™ is a first-in-class, one-time autologous cell and gene therapy designed to break tumor-induced immune suppression by enabling the sustained, targeted expression of an immunotherapeutic payload directly within the TME.

The manufacturing process begins with apheresis collection of the patient's own HSPCs. A functional copy of the therapeutic gene — encoding interferon alpha (IFN-α) — is inserted into the HSPCs via ex vivo transduction using a non-replicating lentiviral vector (LVV). Lentiviral vectors are considered the preferred tool for ex vivo HSPC engineering in clinical settings due to their ability to efficiently transduce HSPCs with large transgene payloads and their established safety profile across multiple clinical programs.

Once reinfused, the engineered HSPCs give rise to bone marrow-derived myeloid cells that home to solid tumors, differentiate into TEMs, and locally release IFN-α within the TME. IFN-α exerts anti-tumor activity through multiple complementary mechanisms: direct induction of cancer cell apoptosis, inhibition of tumor vascularization, and restoration of anti-tumor adaptive immune responses — including activation of tumor-reactive T cells. By delivering IFN-α locally rather than systemically, Temferon aims to restore the immunogenic potential of the TME while avoiding the systemic toxicities that historically limited IFN-α use in oncology.

Temferon is designed as a one-time monotherapy, with additional potential to significantly enhance the efficacy of other approved therapeutics — including immune checkpoint inhibitors — when used in combination. The platform is broadly applicable across solid tumor types characterized by intratumoral TEM infiltration.